the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Official Title Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Principal Investigator O'Donnell, Peter
Brief Summary This is a single arm open label multi-institutional phase II trial of olaparib monotherapy in subjects with metastatic urothelial cancer harboring somatic DNA damage response (DDR) alterations. The primary objective of the study is to estimate the objective response rate (per RECIST 1.1) to treatment with olaparib.
Gender All
Ages 18 Years
Enrollment 30
Accepts Healthy Volunteers No
Lead Sponsor Matthew GalskyOther
Collaborator Icahn School of Medicine at Mount SinaiOther
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Metastatic Urothelial Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI